Meeting Banner
Abstract #4220

Translating FMRI and DTI Biomarkers from Academic Studies to Global Clinical Trials in Alzheimers Disease

Lea E. Marais1, Jean-Franois Mangin2, 3, Cyril Poupon2, 3, Urielle Thoprakarn2, 3, Vincent Perlbarg4, Gareth J. Barker5, Xavier Golay6, Joseph V. H

1IXICO Ltd., London, United Kingdom; 2IBM NeuroSpin, CEA, Gif-sur-Yvette, France; 3CATI, Gif-sur-Yvette, France; 4UMR-S 678, Laboratoire d'Imagerie Fonctionnelle, Inserm and UPMC Univ Paris06, Paris, France; 5Centre for Neuroimaging Sciences, King's College London, Institute of Psychiatry,, London, United Kingdom; 6MR Neurophysics and Translational Neuroscience, UCL Institute of Neurology, National Hospital for Neurology & Neurosurgery, London, United Kingdom; 7Robert Steiner MRI Unit,Imaging Sciences Department, MRC Clinical Sciences, Hammersmith Hospital, Imperial College London, London, United Kingdom; 8Translational Medicine, Eli Lilly and Company, Indianapolis, United States

Diffusion Tensor Imaging (DTI) and resting state functional Magnetic Resonance Imaging (rs-fMRI) biomarkers correlate with Alzheimers Disease stage and provide additional information on the efficacy of new treatments. Multi-centre clinical studies are essential for rapid enrolment of a sufficient number of patients. We deployed ADNI-style fMRI and DTI sequences on Philips and Siemens 3T scanners and evaluated their repeatability and reproducibility on healthy volunteers. The variability across scanners was comparable to the within-scanner variability. These sequences are thus suitable for the acquisition of comparable data in multi-site, multi-vendor clinical trials.